Home

 Accelerate Your Clinical Research Projects Clinical Trial Evaluation Approval Performances
Share

Approval Performances

Filters (0)
Apply filters

37-48 of 98 results

Clear filters
CESP359A12101
Prostate Cancer Phase I
  • 9.8 weeks
CGCJ904A12101
Solid tumors Phase I
  • 7.2 weeks
  • 1st site activated in Canada
CJSB462B12201
Prostate Cancer Phase II
  • 8.4 weeks
CMAS825J12201
Still's Disease Phase II
  • 8.4 weeks
  • 2nd site activated worldwide
CMAS825J12201
Still's Disease Phase II
  • 10.2 weeks
  • 3rd site activated worldwide
CO45042 (KRAScendo-2) 
Oncology (Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer) Phase III
  • 9.2 weeks
CO45042 (KRAScendo-2) 
Oncology (Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer) Phase III
  • 9.6 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
  • 7.8 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
  • 11.4 weeks
D6972C00002
Chronic Kidney Disease and High Blood Pressure Phase III
  • 14.6 weeks
EFC18418 (CEREN-1)
Chronic Rhinosinusitis with Nasal Polyps Phase III
  • 9.8 weeks
  • 1st site activated in Canada
EFC18418 (CEREN-1)
Chronic Rhinosinusitis with Nasal Polyps Phase III
  • 10.4 weeks
  • 2nd site activated in Canada
GenePHIT
Heart Failure Phase II
  • 11.6 weeks
  • 1st site activated in Canada
GenePHIT
Heart Failure Phase II
  • 13 weeks
  • Canadian FPI
GenePHIT
Heart Failure Phase II
  • 7 weeks
GenePHIT
Heart Failure Phase II
  • 9.4 weeks
GenePHIT
Heart Failure Phase II
  • 12.6 weeks
GenePHIT
Heart Failure Phase II
  • 18.4 weeks
IM045-1018/BALANCE-MSS-1
Neurology Phase II
  • 14.8 weeks
KRAScendo 1 (BO45217)
Non-Small Cell Lung Cancer (NSCLC) Phase III
  • 9.6 weeks
  • 2nd site activated in Canada
MARITIME-CV-20220196
ASCVD and Obesity Phase III
  • 3.8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
  • 8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
  • 8.4 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
  • 11.8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
  • 15 weeks
MARITIME-HF-20230227
Obesity and Heart Failure Phase III
  • 12 weeks

Use the FAST TRACK Evaluation Service to Start Your Clinical Trials

Learn more Contact us